Once weekly injection of semaglutide causes weight loss in obese patients with heart failure with preserved ejection fraction (HFpEF), with positive shifts in symptoms and improvements in physical limitations in the STEP-HFpEF trial presented at ESC 2023.
In percutaneous coronary intervention (PCI) for complex bifurcation lesions, optical coherence tomography (OCT) guidance outdid the angiography-guided approach, findings from the OCTOBER* trial have shown.
In cancer patients with isolated distal deep vein thrombosis (IDDVT), a 12-month anticoagulation regimen with the oral factor Xa inhibitor edoxaban fared better than a 3-month regimen, findings from the ONCO DVT study have shown.
Alirocumab administered every 2 or 4 weeks (Q2W or Q4W dosing regimen) significantly reduced low-density lipoprotein-cholesterol (LDL-C) levelsin paediatric patients with heterozygous familial hypercholesterolaemia (HeFH), according to a study presented at ESC 2023.
Catheter ablation boosts outcomes in patients with advanced heart failure (HF) who are being considered for heart transplantation or left ventricular assist device (LVAD) implantation in the CASTLE-HTx trial presented at ESC 2023.
Extended clopidogrel monotherapy after a 9- to 12-month course of dual antiplatelet therapy (DAPT) reduces bleeding and ischaemic events in patients with acute coronary syndrome (ACS) who are at high risk for both events, according to the OPT-BIRISK* trial presented at ESC 2023.
Treatment with qiliqiangxin (QLQX), a traditional Chinese medicine (TCM), significantly reduces the risk of hospitalization due to heart failure and cardiovascular (CV) death in patients with heart failure and reduced ejection fraction (HFrEF), according to the QUEST* trial presented at ESC 2023
The HEART-FID trial narrowly missed its primary endpoint, showing modest improvement in all-cause mortality, heart failure hospitalizations (hHF), and exercise function with ferric carboxymaltose (FCM) in HFrEF* patients with iron deficiency (ID).
In the treatment of patients with paroxysmal atrial fibrillation (AF), pulse field ablation (PFA) system appears to yield safety and efficacy outcomes that are noninferior to those of conventional thermal ablation, according to data from the ADVENT trial.